atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
The company has confirmed that the deceased are 39
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Subscribe To Our Newsletter & Stay Updated
